Last reviewed · How we verify

Humoral hypercalcemia of malignancy — Treatment Landscape & Competitive Intelligence

Humoral hypercalcemia of malignancy (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Humoral hypercalcemia of malignancy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zometa ZOLEDRONIC ACID Novartis zoledronic acid Farnesyl pyrophosphate synthase 2001-01-01
Didronel ETIDRONIC ACID Procter And Gamble Bisphosphonate 1977-01-01
Depo-Medrol METHYLPREDNISOLONE ACETATE Pfizer Corticosteroid Glucocorticoid receptor 1959-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortifoam HYDROCORTISONE ACETATE Pfizer Corticosteroid Corticosteroid-binding globulin 1951-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 6 drugs in Humoral hypercalcemia of malignancy
  2. Pfizer · 3 drugs in Humoral hypercalcemia of malignancy
  3. Generic (originally Schering) · 2 drugs in Humoral hypercalcemia of malignancy
  4. Children's Hospital Medical Center, Cincinnati · 1 drug in Humoral hypercalcemia of malignancy
  5. Ente Ospedaliero Ospedali Galliera · 1 drug in Humoral hypercalcemia of malignancy
  6. Generic (originally Merck) · 1 drug in Humoral hypercalcemia of malignancy
  7. Generic (originally Merck/Upjohn) · 1 drug in Humoral hypercalcemia of malignancy
  8. Generic (originally Upjohn/Pfizer) · 1 drug in Humoral hypercalcemia of malignancy
  9. Hannover Medical School · 1 drug in Humoral hypercalcemia of malignancy
  10. Leiden University Medical Center · 1 drug in Humoral hypercalcemia of malignancy
  11. Novartis · 1 drug in Humoral hypercalcemia of malignancy
  12. Organon and Co · 1 drug in Humoral hypercalcemia of malignancy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Humoral hypercalcemia of malignancy:

Cite this brief

Drug Landscape (2026). Humoral hypercalcemia of malignancy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/humoral-hypercalcemia-of-malignancy. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing